Experienced in Herniated Disk

Morio E. Matsumoto

Tokyo, JP 
Experienced in Herniated Disk
Tokyo, JP 
OverviewLocationsClinical Research

Overview

Morio Matsumoto practices in Tokyo, Japan. Dr. Matsumoto is rated as an Experienced expert by MediFind in the treatment of Herniated Disk. His top areas of expertise are Lordosis, Multiple Myeloma, Spinal Tumor, Laminectomy, and Spinal Fusion.

His clinical research consists of co-authoring 802 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 6 articles in the study of Herniated Disk.

Gender
Male

Locations

Tokyo, Japan
Other Locations
Shibukawa, Japan
Shinjiku, Japan
Shinjuku, 1608582, Japan
Japan
Shinanomachi, 1608582, Japan
Nagoya, Japan
Sendai, 9808578, Japan
Otsu, Japan
Tsuruoka, 9970052, Japan
Keio, Japan
Sakai, Japan
Shinagawa, 1428555, Japan
Yushima, 1138519, Japan
Toyama, Japan
Suita, Japan
Kobe, 6510072, Japan
Kanazawa, Japan
Tsukuba, 3058585, Japan
Funabashi, 2740082, Japan
Shizuoka, 4228529, Japan
Kashihara, Japan
Nara-shi, Japan
Hongo, 1130033, Japan
Tochigi, Japan
Hirai, 1900182, Japan
Fukushima, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
Enrollment Status: Active_not_recruiting
Publish Date: June 10, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Pom/Dex (Pomalidomide plus Low Dose Dexamethasone)
Study Phase: Phase 3

801 Total Publications

A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant.
A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant.
Journal: Future oncology (London, England)
Published: October 08, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Matsumoto's expertise for a condition
ConditionClose
    View All 17 Distinguished Conditions
    View All 29 Advanced Conditions
    View All 114 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile